Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity of PPSV-23 After PCV-13 Vaccination in Adult Asthmatic Patients

Next Previous
X
Search
Trial Profile

Immunogenicity of PPSV-23 After PCV-13 Vaccination in Adult Asthmatic Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics

    • Most Recent Events

    • 05 Jan 2021 Status changed from recruiting to completed.
    • 16 Mar 2020 Results (N=15), assessing the effect of priming with conjugate PCV13 vaccine prior to PPSV23 to elicits T-cell dependent durable immune responses, published on 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 04 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top